Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark OfficeGlobeNewsWire • 08/23/23
Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar MarketAccesswire • 08/16/23
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business UpdatesGlobeNewsWire • 08/07/23
Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart FailureAccesswire • 07/25/23
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This MarketAccesswire • 07/18/23
Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ:WINT) Is Helping Change ThatAccesswire • 07/14/23
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual MechanismGlobeNewsWire • 06/12/23
Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term MilestonesGlobeNewsWire • 06/05/23
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business UpdatesGlobeNewsWire • 05/15/23
Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of IstaroximeGlobeNewsWire • 04/27/23
Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment OptionGlobeNewsWire • 04/24/23
Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public OfferingGlobeNewsWire • 04/20/23
Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator PatentGlobeNewsWire • 04/17/23
Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business UpdatesGlobeNewsWire • 04/03/23
Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of IstaroximeGlobeNewsWire • 03/06/23
Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart FailureGlobeNewsWire • 02/28/23
Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics ConferenceGlobeNewsWire • 02/27/23
Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark OfficeGlobeNewsWire • 02/24/23
Windtree Therapeutics to Raise $1.0 Million From the Exercise of Previously Issued WarrantsGlobeNewsWire • 01/20/23